NIH Common Fund Metabolomics Consortium Annual Meeting 2022
May 31 @ 8:00 am – June 2 @ 5:00 pm
To view the Video Recordings for this meeting click HERE
This final science meeting of the NIH Common Fund Metabolomics Consortium will provide an opportunity for sharing and celebrating the scientific accomplishments with Consortium members, with NIH staff beyond the Consortium, and more broadly with the scientific community interested in metabolomics. It will include a three-day virtual meeting that will be webcast live as well as recorded for later on-demand viewing.
The NIH Common Fund Metabolomics Stage II Program was initiated in 2018 to address the existing challenges in metabolite identification, overcome analysis and interpretation hurdles, transform the repository into a national resource, and promote best practices. The program funded seven projects (DTCs) for data analysis and interpretation tools that focused on developing computational methods for quantitation, statistical assessment, and subsequent biological interpretation, thereby streamlining metabolomics workflows that were historically been viewed as arduous steps. In addition, five compound identification development cores (CIDCs) were funded to develop harmonized experimental and computational approaches to enhance compound identification of the most significant, biomedically-relevant unknown metabolites. The program also established a Metabolomics Consortium Coordinating Center (M3C) to coordinate the activities of the Program and facilitate community outreach, plus a National Metabolomics Data Repository (NMDR) that holds a large number of metabolomics datasets and a wide array of metabolomics software and analytical tools for broad community use. More information on the Consortium at NIH Common Fund Stage 2 Metabolomics Consortium – Metabolomics Info
The meeting will include a welcome and brief overview, followed by presentations from the M3C, the NMDR, the 5 CIDCs and the 7 DTCs. It will also include a 90-minute roundtable discussion on day 2 addressing continued challenges in metabolomics moving forward, plus reports from Consortium collaborative projects and working groups, and thirty